Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,

Slides:

Advertisements

Similar presentations

Results of a Randomized Study of the JAK Inhibitor Ruxolitinib (INC424) versus Best Available Therapy (BAT) in Primary Myelofibrosis (PMF), Post- Polycythemia.

Advertisements

Making Proteins in the Powerhouse B. Martin Hällberg, Nils-Göran Larsson Cell Metabolism Volume 20, Issue 2, Pages (August 2014) DOI: /j.cmet

Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.

The Metabolic Basis of Pulmonary Arterial Hypertension Gopinath Sutendra, Evangelos D. Michelakis Cell Metabolism Volume 19, Issue 4, Pages (April.

The Mitochondrial Basis of Aging Nuo Sun, Richard J. Youle, Toren Finkel Molecular Cell Volume 61, Issue 5, Pages (March 2016) DOI: /j.molcel

Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled.

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma Kyung Ah Yoh, Ho Sup Lee,

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management Jorge E. Cortes, Carlos.

VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.

Volume 10, Issue 7, Pages (July 2018)

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower- Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005.

Yuji Nakamoto Clinical Lymphoma, Myeloma and Leukemia

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data Kathleen Lang,

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

New Japanese Initiatives on Stem Cell Therapies

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care.

Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for.

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission Quoc Truong,

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma Pallawi Torka, Priyank Patel, Wei Tan,

Once-Daily Gastroretentive Gabapentin for Postherpetic Neuralgia: Integrated Efficacy, Time to Onset of Pain Relief and Safety Analyses of Data From Two.

Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML Benyam Muluneh, Kaitlyn Buhlinger,

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease Elana A. Maser, Renata Villela,

Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review Trent P. Wang, Steven G.

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I Ruben A. Mesa, Srdan Verstovsek,

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis Moussab.

Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France Nicolas Despiégel, Chantal Touboul, Alain.

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma Shumaila.

Targeting T Cell Co-receptors for Cancer Therapy

Psychological response and survival in breast cancer

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Vertebral Fracture Risk of Multiple Myeloma Assessed by a CT-based Finite Element and Trabecular Structure Analysis Miyuki Takasu, Yoko Kaichi, Kazuo.

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.

Pradnya Chopade, Luke P. Akard Clinical Lymphoma, Myeloma and Leukemia

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera.

Clinical Lymphoma, Myeloma and Leukemia

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data Preetesh Jain, Hagop Kantarjian,

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

Neuropsychological Assessment of Sport-Related Concussion

Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid.

A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic.

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration Julio.

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi,

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review Jill A. Bell, Aaron.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

Volume 368, Issue 9541, Pages (September 2006)

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study Jorge E.

Nutrition and Metabolism of the Surgical Patient, Part II

Clinical Lymphoma, Myeloma and Leukemia

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Choosing outcome variables: global assessment and diaries

Autologous Stem Cell Transplantation for POEMS Syndrome

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Presentation transcript:

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa, William Sun, Michael Montgomery, Srdan Verstovsek Clinical Lymphoma, Myeloma and Leukemia Volume 17, Issue 8, Pages 479-487 (August 2017) DOI: 10.1016/j.clml.2017.05.015 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 Change From Baseline in Spleen Size. (A) Mean Percentage Change From Baseline to Week 12 in Spleen Length and Spleen Volume. (B) Mean (SE) Percentage Change From Baseline in Spleen Volume Over Time. ∗1 Patient Did Not Have an Evaluable Spleen Volume Assessment and Was Excluded From the Spleen Volume Calculation. †2 Patients Did Not Have Evaluable Spleen Volume Assessments and Were Excluded From the Spleen Volume Calculation Clinical Lymphoma, Myeloma and Leukemia 2017 17, 479-487DOI: (10.1016/j.clml.2017.05.015) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 2 Proportion of Patients Reporting “Much Improved” or “Very Much Improved” on the PGIC at Week 12 Abbreviation: PGIC = Patient Global Impression of Change. Clinical Lymphoma, Myeloma and Leukemia 2017 17, 479-487DOI: (10.1016/j.clml.2017.05.015) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 3 Mean Percentage Change From Baseline to Week 12 in MFSAF TSS and Individual Symptom Scores. The Number of Evaluable Patients in Each Group Ranged as Follows. Ruxolitinib: ≥ 50% Reduction, 40 to 53; 25% to < 50% Reduction, 34 to 41; 10% to < 25% Reduction, 14 to 21; < 10% Reduction, 9 to 15; Worsening, 6 to 9; Placebo: 97 to 129 Abbreviations: MFSAF = Myelofibrosis Symptom Assessment Form; TSS = total symptom score. Clinical Lymphoma, Myeloma and Leukemia 2017 17, 479-487DOI: (10.1016/j.clml.2017.05.015) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 4 Mean Change From Baseline to Week 12 in PROMIS Fatigue Scale Score Abbreviation: PROMIS = Patient-Reported Outcomes Measurement System. Clinical Lymphoma, Myeloma and Leukemia 2017 17, 479-487DOI: (10.1016/j.clml.2017.05.015) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 5 Mean Change From Baseline to Week 12 in Metabolic Measures. Assessed Measures Were (A) Body Weight and (B) Serum Albumin Clinical Lymphoma, Myeloma and Leukemia 2017 17, 479-487DOI: (10.1016/j.clml.2017.05.015) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 6 Overall Survival. Patients in the Ruxolitinib Group Were Analyzed in 3 Subgroups on the Basis of Reduction From Baseline in Spleen Length at Week 12: ≥ 50%, 25% to < 50%, and < 25% (Including Worsening Spleen Length) Clinical Lymphoma, Myeloma and Leukemia 2017 17, 479-487DOI: (10.1016/j.clml.2017.05.015) Copyright © 2017 Elsevier Inc. Terms and Conditions